Q2 FY27 swings to profit on property sale as revenue rises 7.4%

Going-concern doubtEmphasis of matterEBITDA margin expansionExceptional itemResults View source PDF Explain this filing

INDOCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹219.10

prior close

₹232.25

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.7%-1.7% vs market

Pharmaceuticals peers, median of 173sector+2.0%-1.9% vs sector

On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

-0.8

15m

-1.6

30m

-2.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+1.7-1.7+2.0-1.9

Next day

-2.2+1.8-4.0+2.6-4.9

-4.6+2.5-7.0+2.7-7.3

-4.2-0.1-4.1+2.0-6.2

-1.4+1.4-2.8+2.1-3.5

-2.4+1.6-4.1+2.2-4.7

-1.9+5.0-6.9+3.9-5.8

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q2 and H1 FY27 results ended 30 September 2026. Consolidated revenue rose 7.4% to Rs 506.9 crore in Q2 and 7.8% to Rs 973.1 crore in H1; EBITDA margin improved to 9.2% and 9.0%. Net profit was Rs 19.47 crore in Q2 and Rs 84.92 crore in H1, helped by exceptional gains of Rs 37.14 crore and Rs 134.48 crore. The Q2 gain mainly came from an Andheri property sale. Profit excluding exceptional items was negative.

Likely market impact

Profit relies on a one-off property sale while core losses persist. Two units have negative net worth, raising going-concern and impairment risk.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹520.2 Cr	₹484.7 Cr	+7.3%
Operating profit	−₹14.92 Cr	−₹13.76 Cr	loss widened
Profit after tax	₹19.47 Cr	−₹9.21 Cr	turned positive
EBITDA margin	16.1%	8.8%	+7.3 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.